Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7389 liposomal formulation plus nivolumab in solid tumors
jRCT2080224876Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin liposomal and nivolumab in Nonhematologic neoplasms, gastric cancer (GC), Esophagogastric Cancer and 1 more, sponsored by Eisai Co., Ltd. Started Sep 2019; status: completed.
02
Drugs
eribulin liposomalnivolumab
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)Esophagogastric Cancersmall cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2080224876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224876.